These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 9755458

  • 1. [Genetic polymorphism of the CYP2C subfamily].
    Chiba K.
    Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458
    [Abstract] [Full Text] [Related]

  • 2. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T.
    Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
    [Abstract] [Full Text] [Related]

  • 3. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
    Chang TK, Yu L, Goldstein JA, Waxman DJ.
    Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
    [Abstract] [Full Text] [Related]

  • 4. Biochemistry and molecular biology of the human CYP2C subfamily.
    Goldstein JA, de Morais SM.
    Pharmacogenetics; 1994 Dec; 4(6):285-99. PubMed ID: 7704034
    [Abstract] [Full Text] [Related]

  • 5. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, Kubota T, Kimura S, Echizen H.
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [Abstract] [Full Text] [Related]

  • 6. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM, Wester MR, Aramsombatdee E, Raucy JL.
    Arch Biochem Biophys; 1998 May 01; 353(1):16-28. PubMed ID: 9578596
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian.
    Inoue K, Yamazaki H, Shimada T.
    Xenobiotica; 1998 Apr 01; 28(4):403-11. PubMed ID: 9604303
    [Abstract] [Full Text] [Related]

  • 12. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
    Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, Cha IJ, Flockhart DA, Shin JG.
    Pharmacogenetics; 2002 Mar 01; 12(2):111-9. PubMed ID: 11875365
    [Abstract] [Full Text] [Related]

  • 13. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
    Wester MR, Lasker JM, Johnson EF, Raucy JL.
    Drug Metab Dispos; 2000 Mar 01; 28(3):354-9. PubMed ID: 10681382
    [Abstract] [Full Text] [Related]

  • 14. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H, Inoue K, Shimada T.
    Xenobiotica; 1998 Feb 01; 28(2):103-15. PubMed ID: 9522436
    [Abstract] [Full Text] [Related]

  • 15. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
    Miners J.
    Pharmacogenetics; 2002 Mar 01; 12(2):91-2. PubMed ID: 11875362
    [No Abstract] [Full Text] [Related]

  • 16. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
    Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA.
    Pharmacogenetics; 1996 Aug 01; 6(4):341-9. PubMed ID: 8873220
    [Abstract] [Full Text] [Related]

  • 17. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Hashimoto Y, Otsuki Y, Odani A, Takano M, Hattori H, Furusho K, Iui K.
    Biol Pharm Bull; 1996 Aug 01; 19(8):1103-5. PubMed ID: 8874828
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacogenetics of CYP2C subfamily in a Japanese population.
    Ieiri I, Higuchi S.
    J Toxicol Sci; 1998 Jul 01; 23 Suppl 2():129-31. PubMed ID: 9760448
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.